CN106418529A - 提高免疫力的菊花口服液制备方法及其口服液 - Google Patents
提高免疫力的菊花口服液制备方法及其口服液 Download PDFInfo
- Publication number
- CN106418529A CN106418529A CN201610620899.6A CN201610620899A CN106418529A CN 106418529 A CN106418529 A CN 106418529A CN 201610620899 A CN201610620899 A CN 201610620899A CN 106418529 A CN106418529 A CN 106418529A
- Authority
- CN
- China
- Prior art keywords
- parts
- flos chrysanthemi
- oral liquid
- component
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 54
- 230000036039 immunity Effects 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 235000007516 Chrysanthemum Nutrition 0.000 title abstract description 17
- 244000189548 Chrysanthemum x morifolium Species 0.000 title description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 73
- 239000003814 drug Substances 0.000 claims abstract description 67
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 239000006228 supernatant Substances 0.000 claims abstract description 10
- 229920001353 Dextrin Polymers 0.000 claims abstract description 8
- 239000004375 Dextrin Substances 0.000 claims abstract description 8
- 235000019425 dextrin Nutrition 0.000 claims abstract description 8
- 230000001954 sterilising effect Effects 0.000 claims abstract description 3
- 241000628997 Flos Species 0.000 claims description 90
- 229940079593 drug Drugs 0.000 claims description 28
- 238000000605 extraction Methods 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 19
- 239000000706 filtrate Substances 0.000 claims description 17
- 230000008901 benefit Effects 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 235000019640 taste Nutrition 0.000 claims description 11
- 238000000108 ultra-filtration Methods 0.000 claims description 11
- 238000005325 percolation Methods 0.000 claims description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 239000008517 radix Trichosanthis Substances 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 6
- 229910001220 stainless steel Inorganic materials 0.000 claims description 6
- 239000010935 stainless steel Substances 0.000 claims description 6
- 230000000844 anti-bacterial effect Effects 0.000 claims description 5
- 239000012567 medical material Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 238000007598 dipping method Methods 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 3
- 235000011613 Pinus brutia Nutrition 0.000 claims description 3
- 241000018646 Pinus brutia Species 0.000 claims description 3
- 229910000831 Steel Inorganic materials 0.000 claims description 3
- 235000011837 pasties Nutrition 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 239000010959 steel Substances 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 2
- 235000012907 honey Nutrition 0.000 claims description 2
- 238000011068 loading method Methods 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 53
- 210000004369 blood Anatomy 0.000 abstract description 52
- 210000000952 spleen Anatomy 0.000 abstract description 25
- 210000004072 lung Anatomy 0.000 abstract description 12
- 238000000034 method Methods 0.000 abstract description 12
- 239000000047 product Substances 0.000 abstract description 12
- 230000036772 blood pressure Effects 0.000 abstract description 10
- 210000001508 eye Anatomy 0.000 abstract description 9
- 239000000284 extract Substances 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 4
- 235000012000 cholesterol Nutrition 0.000 abstract description 2
- 230000003860 sleep quality Effects 0.000 abstract description 2
- 241000723353 Chrysanthemum Species 0.000 abstract 7
- 230000000249 desinfective effect Effects 0.000 abstract 1
- 230000002028 premature Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 31
- 230000000694 effects Effects 0.000 description 31
- 201000010099 disease Diseases 0.000 description 28
- 210000004185 liver Anatomy 0.000 description 25
- 231100000614 poison Toxicity 0.000 description 18
- 208000002193 Pain Diseases 0.000 description 17
- 230000036407 pain Effects 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 15
- 244000052769 pathogen Species 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 230000004438 eyesight Effects 0.000 description 13
- 239000003440 toxic substance Substances 0.000 description 13
- 206010011224 Cough Diseases 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 210000003734 kidney Anatomy 0.000 description 12
- 210000000056 organ Anatomy 0.000 description 12
- 230000007774 longterm Effects 0.000 description 11
- 230000000242 pagocytic effect Effects 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 10
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 239000002398 materia medica Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 208000002173 dizziness Diseases 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 208000033065 inborn errors of immunity Diseases 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 206010019233 Headaches Diseases 0.000 description 7
- 206010037660 Pyrexia Diseases 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 231100000869 headache Toxicity 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000001541 thymus gland Anatomy 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 230000035619 diuresis Effects 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 6
- 229960004844 lovastatin Drugs 0.000 description 6
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 6
- 244000000010 microbial pathogen Species 0.000 description 6
- 239000002574 poison Substances 0.000 description 6
- 238000010791 quenching Methods 0.000 description 6
- 230000000306 recurrent effect Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000035922 thirst Effects 0.000 description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
- 244000269722 Thea sinensis Species 0.000 description 5
- 208000009205 Tinnitus Diseases 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229930003944 flavone Chemical class 0.000 description 5
- 235000011949 flavones Nutrition 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 231100000886 tinnitus Toxicity 0.000 description 5
- 235000015961 tonic Nutrition 0.000 description 5
- 230000001256 tonic effect Effects 0.000 description 5
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- DANYIYRPLHHOCZ-UHFFFAOYSA-N 5,7-dihydroxy-4'-methoxyflavone Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 DANYIYRPLHHOCZ-UHFFFAOYSA-N 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- 208000008035 Back Pain Diseases 0.000 description 4
- 206010010726 Conjunctival oedema Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 206010023644 Lacrimation increased Diseases 0.000 description 4
- 208000008930 Low Back Pain Diseases 0.000 description 4
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 4
- 244000042430 Rhodiola rosea Species 0.000 description 4
- 235000003713 Rhodiola rosea Nutrition 0.000 description 4
- 208000012886 Vertigo Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 210000000232 gallbladder Anatomy 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 201000001881 impotence Diseases 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- 230000004317 lacrimation Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000003014 reinforcing effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 231100000889 vertigo Toxicity 0.000 description 4
- 239000011800 void material Substances 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 3
- CMUNUTVVOOHQPW-LURJTMIESA-N L-proline betaine Chemical class C[N+]1(C)CCC[C@H]1C([O-])=O CMUNUTVVOOHQPW-LURJTMIESA-N 0.000 description 3
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Chemical class O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 206010043866 Tinea capitis Diseases 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 150000002212 flavone derivatives Chemical class 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000010341 ping gan Substances 0.000 description 3
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 3
- 229960002646 scopolamine Drugs 0.000 description 3
- CMUNUTVVOOHQPW-ZCFIWIBFSA-N stachydrine Chemical class C[N+]1(C)CCC[C@@H]1C([O-])=O CMUNUTVVOOHQPW-ZCFIWIBFSA-N 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 208000009189 tinea favosa Diseases 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Chemical class O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical class NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 240000007087 Apium graveolens Species 0.000 description 2
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 2
- 235000010591 Appio Nutrition 0.000 description 2
- 206010063659 Aversion Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 description 2
- 206010010144 Completed suicide Diseases 0.000 description 2
- 206010015958 Eye pain Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- WNGSUWLDMZFYNZ-UHFFFAOYSA-N Leonurine Chemical compound COC1=CC(C(=O)OCCCCN=C(N)N)=CC(OC)=C1O WNGSUWLDMZFYNZ-UHFFFAOYSA-N 0.000 description 2
- 241000234280 Liliaceae Species 0.000 description 2
- 241000217407 Margaritifera Species 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 240000000249 Morus alba Species 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010059013 Nocturnal emission Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 244000236658 Paeonia lactiflora Species 0.000 description 2
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 2
- 244000046146 Pueraria lobata Species 0.000 description 2
- 235000010575 Pueraria lobata Nutrition 0.000 description 2
- 240000006079 Schisandra chinensis Species 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 244000178320 Vaccaria pyramidata Species 0.000 description 2
- 235000010587 Vaccaria pyramidata Nutrition 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 235000009962 acacetin Nutrition 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- -1 analgesia Substances 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000010238 camphora Substances 0.000 description 2
- 229940025250 camphora Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical class C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 208000013116 chronic cough Diseases 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- NJYVDFDTLLZVMG-UHFFFAOYSA-N echinacoside Chemical class CC1OC(OC2C(O)C(OCCc3ccc(O)c(O)c3)OC(COC4OC(CO)C(O)C(O)C4O)C2OC(=O)C=Cc5cc(O)cc(O)c5)C(O)C(O)C1O NJYVDFDTLLZVMG-UHFFFAOYSA-N 0.000 description 2
- FSBUXLDOLNLABB-ISAKITKMSA-N echinacoside Chemical class O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FSBUXLDOLNLABB-ISAKITKMSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 239000011344 liquid material Substances 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 2
- 235000009498 luteolin Nutrition 0.000 description 2
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 2
- 235000012771 pancakes Nutrition 0.000 description 2
- 230000024241 parasitism Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000010181 polygamy Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 229930193551 sterin Natural products 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010005913 Body tinea Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 241000189115 Catananche Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000220284 Crassulaceae Species 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241000208686 Eucommiaceae Species 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 235000018958 Gardenia augusta Nutrition 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- VELYAQRXBJLJAK-MJSCJBMMSA-N Leonuridine Chemical compound C12C(C)(O)CC(O)C2C=COC1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VELYAQRXBJLJAK-MJSCJBMMSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000222065 Lycoperdon Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000972673 Phellodendron amurense Species 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241000756042 Polygonatum Species 0.000 description 1
- 241001633680 Polygonatum odoratum Species 0.000 description 1
- 241000037831 Polygonatum sibiricum Species 0.000 description 1
- 241000768494 Polymorphum Species 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 244000234609 Portulaca oleracea Species 0.000 description 1
- 235000001855 Portulaca oleracea Nutrition 0.000 description 1
- 241000219304 Portulacaceae Species 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 102000004330 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 241001107098 Rubiaceae Species 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241000736078 Schisandra sphenanthera Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000316351 Taxillus sutchuenensis Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000002115 aflatoxin B1 Substances 0.000 description 1
- OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical compound C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 description 1
- 229930020125 aflatoxin-B1 Natural products 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000003555 analeptic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004345 fruit ripening Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000003864 humus Substances 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000003526 lymphopoietic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 230000000191 radiation effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000009394 selective breeding Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003557 thiazoles Chemical class 0.000 description 1
- 201000003875 tinea corporis Diseases 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Abstract
本发明公开了一种提高免疫力的菊花口服液制备方法,包括以下步骤:a.菊花的萃取,作为组分1;b.其他原料的制备,作为组分2;c.将上述两种提取液组分1和组分2合并,浓缩后加糊精调和,消毒杀菌后制备成口服液。所述步骤b中,将其余原料泡入重量10倍量乙醇中2‑3天后,加热提取2次,每次1‑2小时,取上清液,合并提取液,100‑110目滤过。本发明中,菊花能健脾润肺降脂、降血脂、降血压、降低胆固醇、降低血糖,使血液的成份得到净化,本发明没有难闻难以下咽的中药味,使人易于接受,可以长期服用。能改善亚健康人群易感冒、眼睛酸涩、睡眠质量不高,脾虚乏力须发早白;体虚赢瘦等症状。
Description
技术领域
本发明涉及含有来源于植物组份的提高免疫力的保健品,特别涉及一种提高免疫力的菊花口服液及其制备方法。
背景技术
数百万年来,人类在生活一个既适合生存又充满危险的环境,人类得以存续,也获得了非凡的免疫力。所以说免疫力是生物进化过程的产物。
免疫力是人体自身的防御机制,是人体识别和消灭外来侵入的任何异物(病毒、细菌等);处理衰老、损伤、死亡、变性的自身细胞以及识别和处理体内突变细胞和病毒感染细胞的能力。现代免疫学认为,免疫力是人体识别和排除“异己”的生理反应。人体内执行这一功能的是免疫系统。
免疫力按其获得方式的不同可分为:1。先天性免疫,是人一生下来就有的。如猪瘟在猪群中传播很快,但和人类无缘。这是因为人类天生就不会得这种病;2。获得性免疫,是人生下来以后在生活过程中自然获得的,或者用人工辅助的方法被动得到。
免疫力低下的身体易于被感染或患癌症;免疫力超常也会产生对身体有害的结果,如引发过敏反应、自身免疫疾病等。
各种原因使免疫系统不能正常发挥保护作用,在此情况下,极易招致细菌、病毒、真菌等感染,因此免疫力低下最直接的表现就是容易生病。因经常患病,加重了机体的消耗,所以一般有体质虚弱、营养不良、精神萎靡、疲乏无力、食欲降低、睡眠障碍等表现,生病、打针吃药便成了家常便饭。每次生病都要很长时间才能恢复,而且常常反复发作。长此以往会导致身体和智力发育不良,还易诱发重大疾病。
深层原因是免疫力低下或免疫力不健全。当人体免疫功能失调,或者免疫系统不健全时,下列问题就会反复发作:--感冒反复发作、扁桃体炎反复发作、哮喘反复发作、支气管炎反复发作、肺炎反复发作、腹泻反复发作……所以千万不可小视。
免疫力是指机体抵抗外来侵袭,维护体内环境稳定性的能力。空气中充满了各种各样的微生物:细菌、病毒、支原体、衣原体、真菌等等。在人体免疫力低下的情况下,它们都可以成为感早班的病原体。虽然人体对不同的病原体会产生相应的抗体,以抵御再次感染,但抗体具有专一性和时限性,比如链球菌抗体只能在较短时期内保护机体不受链球菌的再次侵犯,也并不能抵御其他病毒的感染。免疫力低下的人根本无法抵御感冒病毒的侵袭,这才是他频繁感冒的真正原因。
菊花,多年生菊科草本植物,是经长期人工选择培育出的名贵观赏花卉,也称艺菊,品种已达千余种。菊花是中国十大名花之一,在中国已有三千多年的栽培历史,中国菊花传入欧洲,约在明末清初开始。其中产地湖北大别山麻城福田河的福白菊,浙江桐乡的杭白菊和黄山脚下的黄山贡菊(徽州贡菊)比较有名。产于安徽亳州的亳菊、滁州的滁菊、四川中江的川菊、浙江德清的德菊、河南济源的怀菊花(四大怀药之一)都有很高的药效。特别是黄山贡菊,它生长在高山云雾之中,采黄山之灵气,汲皖南山水之精华,它的无污染性对现代人来说,具有更高的饮用价值。
菊花的功效与作用:味微辛、甘、苦,性微寒。能疏散风热,清肝明目,平肝阳,解毒。用于感冒风热,发热头昏;肝经有热;目赤多泪,或肝肾阴虚,眼目昏花;肝阳上亢,眩晕头痛;疮疡肿痛。现代又用于冠心病、高血压病。
降血压:菊花具有降血压、消除癌细胞、扩张冠状动脉和抑菌的作用,长期饮用能增加人体钙质、调节心肌功能、降低胆固醇,适合中老年人和预防流行性结膜炎时饮用。
明目:菊花除了涂抹眼睛可消除浮肿之外,平常可以泡一杯菊花茶来喝,能消除眼睛疲劳。如果每天喝3-4杯的菊花茶,对恢复视力也有一定作用。
提神:菊花是一种神经强壮剂,能增强毛细血管的抵抗力,可延缓衰老,增强体力。菊花有良好的镇静作用,经常食用能使人肢体轻松,醒脑提神。菊花的营养价值
菊花的主要成分有挥发油(0.20-/0-0.85%)、腺嘌呤、胆碱、水苏碱、菊苷及黄酮类化合物。挥发油主要有龙脑、樟脑、菊酮和醋酸龙脑酷等成分,黄酮类成分有木樨草素、芹菜素、刺槐素等。此外,菊花中还含有丰富的维生素、氨基酸、微量元素等。杭白菊中维生素E含量较高。
《本草纲目》:风热,目疼欲脱,泪出,养目去盲,作枕明目。《本经》:诸风头眩肿痛,目欲脱,泪出,皮肤死肌,恶风湿痹。久服利血气,轻身耐老延年。《别录》:疗腰痛去来陶陶,除胸中烦热,安肠胃,利五脉,调四肢。《本草衍义》:近世有二十余种,惟单叶花小而黄,绿叶色深小而薄,应候而开者是也。
菊花疏风较弱,清热力佳,用于外感风热常配桑叶同用,也可配黄芩、山栀治热盛烦燥等症。菊花治目赤肿痛,无论属于肝火或风热引起者,均可应用,因本品既能清肝火,又能散风热,常配合蝉衣、白蒺藜等同用。如肝阴不足,眼目昏花,则多配生地、杞子等同用。菊花清热解毒之功甚佳,为外科要药,主要用于热毒疮疡、红肿热痛之症,特别对于疔疮肿痛毒尤有良好疗效,既可内服,又可捣烂外敷。临床上常与地丁草、蒲公英等清热解毒之品配合应用。菊花能平降肝阳,对肝阳上亢引起的头目眩晕,往往与珍珠母、葛藤等配伍应用。
菊花一药,主要分白菊、黄菊、野菊。黄、白两菊,都有疏散风热、提高免疫力、清热解毒的功效。白菊花味甘、清热力稍弱,长于提高免疫力;黄菊花味苦,泄热力较强,常用于疏散风热;野菊花味甚苦,清热解毒的力量很强。野菊的茎、叶,功用与花相似,无论内服与外敷,都有功效。桑叶与菊花,均能疏散风热,清泄肺肝,故在外感风热、发热头痛及目赤肿痛等症,两药往往相辅为用。但桑叶疏风清肺的功效较好,故治肺燥咳嗽,往往用桑叶而不用菊花;菊花则长于平肝阳,且能清热解毒。
对于大多数高血压患者来说,单一药物治疗依旧无法控制血压,而药物剂量增加常伴随不良反应加重(如ACEI引起的咳嗽),患者往往难以忍受,这时依据不同类别降压药的降压机制上的协同作用,可以使得降压效果增大而不增加或较小增加不良反应,我们一般选择小剂量的两种或两种以上的抗高血压药物联合应用以使得血压达标。
俗话说“是药三分毒”,现在市面上出售的各种保健品、药品鱼龙混杂,大多数只是虚假宣传的噱头,有的不仅没有保健成分,还造成人身体的巨大伤害。可是中药气味清苦,很多人不愿长期服用;即使服用,是药三分毒,让人长期服用时也产生抗拒心理。怎么把菊花的功效发挥到最大又不伤害人体,并且明显改善口感,使人能接受,是我们迫切需要解决的问题。
发明内容
本发明所要解决的技术问题在于,现代人的免疫力正变得越来越脆弱,环境污染,作息不规律、生活节奏快、吃的不健康,不知节欲,造成各种疾病的发病率都在不断上升。尤其所谓的办公室一族,更是免疫力低下的高发人群。大部分人都是亚健康状态,在透支原本就不健康的身体。大部分人的症状为易感冒、眼睛酸涩、脾虚乏力;食少口干;消渴;肾亏腰膝酸软;阳痿遗精;耳鸣目暗;须发早白;体虚赢瘦;风癞癣疾。什么是安全有效的活性物质保健品,能大大提高免疫力,增强体质?一直是人们期待解决问题的关键。中药气味清苦,很多人不愿长期服用;即使服用,是药三分毒,让人长期服用时也产生抗拒心理。
为解决上述技术问题,本发明提供一种提高免疫力的菊花口服液,其所述菊花口服液中可以包括以下重量份的原料药:菊花10~50份,桑寄生10~20份,黄精10~20份,桑叶10~20份,山茱萸10~20份,莪术10~20份,五味子10~20份,杜仲10~20份,玉竹10~20份,马齿苋10~20份,天花粉10~20份,栀子10~20份,地骨皮10~20份,益母草10~20份,合欢皮10~20份,红景天10~20份,丹皮10~20份。
所述提高免疫力的菊花口服液,其所述菊花口服液中还可以包括以下重量份的原料药:菊花10~40份,桑寄生10~15份,黄精10~15份,桑叶10~15份,山茱萸10~15份,莪术10~15份,五味子10~15份,杜仲10~15份,玉竹10~15份,马齿苋10~15份,天花粉10~20份,栀子10~20份,地骨皮10~20份,益母草10~20份,合欢皮10~20份,红景天10~20份,丹皮10~20份。
所述提高免疫力的菊花口服液,其所述菊花口服液中也可以包括以下重量份的原料药:菊花10~30份,桑寄生10~20份,黄精10~20份,桑叶10~20份,山茱萸10~20份,莪术10~20份,五味子10~20份,杜仲10~20份,玉竹10~20份,马齿苋10~20份,天花粉10~15份,栀子10~15份,地骨皮10~15份,益母草10~15份,合欢皮10~15份,红景天10~15份,丹皮10~15份。
为解决上述技术问题,本发明还提供一种提高免疫力的菊花口服液的制备方法,其所述口服液的制备方法包括以下步骤:
a.菊花的萃取,作为组分1;
b.其他原料的制备,作为组分2;
c.将上述两种提取液组分1和组分2合并,浓缩后加糊精调和,消毒杀菌后制备成口服液。
所述步骤a中,可以在秋季将采集的白菊切碎,将其浸泡置于有盖不锈钢桶内,加70%乙醇液,质量为粗颗粒的0.8-1倍,搅拌均匀,湿润密闭放置1小时以上,使充分膨胀;将渗漉筒底部滤板用纱布袋包裹铺平后再将湿润膨胀后的药物样品拌松弄散,然后用不锈钢勺盛粉,均匀的装入渗漉筒,装10-12厘米厚,用T型棒压匀,再按上述操作,一层一层的装入,适当加压,药粉填装不得超过渗漉筒的2/3高处;药粉面上盖不锈钢孔板压牢,打开渗漉筒下面的放料阀,并放一容器,然后缓缓加入70%乙醇液;待排出药粉粉粒之间的空气,并有乙醇流出约20L左右,关闭放料阀,盖上漉筒、浸渍24小时,然后开放料阀进行渗漉,控制渗漉速度一般为1000g药材每分钟流出2~3ml,滤液放入贮液缸内,并将排空时的乙醇液倒入贮液缸;将渗滤液合并静置,静置备用,作为组分1。
所述步骤b中,可以将其余原料泡入10倍量乙醇中2-3天后,加热提取2次,每次1-2小时,取上清液,合并提取液,100-110目滤过,再经截流分子量为6000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.25的滤液,静置备用,成组分2。
所述步骤c中,可以将上述步骤提取的两种提取液,放入双效真空浓缩器中混合,先将滤液浓缩至80℃时相对密度为1.32的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含0.1g浸膏,加糊精调和,消毒杀菌后制备成口服液。
为解决上述技术问题,本发明也提供一种提高免疫力的菊花口服液的制备方法,所述菊花口服液的制备方法还可以包括以下步骤:
a.菊花的制备,作为组分1;
b.将所述其余原料药切碎提取作为组分2;
c.将组分1和组分2混合,浓缩后加适量蜂蜜调和,紫外线消毒杀菌后装瓶。
所述步骤a中,可以将采集的白菊花泡入10倍量乙醇中2-7天后,加热提取2次,每次1-2小时,取上清液,合并提取液,100-110目滤过,再经截流分子量为6000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩至膏状,静置备用,成组分1。
所述步骤b中,可以将其余原料药材混合,切碎过100~120目筛,过筛后细粉备用,粗颗粒放入耐酸碱浸渍锅,在室温下,与70度以上乙醇一起浸渍15~30天,然后加热回流提取2次,每次1~2小时,将2次提取液合并静置,过滤,分离后取滤液;用纱布过滤,残渣中加入50-60%乙醇,60℃-70℃继续浸提2h,每10min搅拌一次,纱布过滤,合并浸提液,浓缩成糊状成为组分2。
本发明使用白菊为主要原料。本发明活血化瘀、健脾润肺、降血脂、降血压、降低胆固醇、降低血糖,使血液的成份得到净化,而且还可以改善微循环、降低毛细血管的脆性,降低其通透性,主治阴虚劳嗽;肺燥咳嗽;脾虚乏力;食少口干;再加上一些活血化瘀,健脾利湿养阴的中药材,这些药材大多口感清淡,不影响菊花的味道,没有难闻难以下咽的中药味,使人易于接受,可以长期服用,能较好的改善亚健康人群易感冒、眼睛酸涩、睡眠质量不高,脾虚乏力;食少口干;消渴;肾亏腰膝酸软;阳痿遗精;耳鸣目暗;须发早白;体虚赢瘦;风癞癣疾的症状,尤其适合老人、儿童、身体羸弱的病患,更能较好的达到提高免疫力的功效。
具体实施方式
中药的保健作用非常强,如果西药容易引起身体出现大量副作用,使人出现不良反应,那中药的毒副作用小与可以长久服用的作用更加明显。
人体免疫是人体对外界的病原微生物等的防御机能,或者说是防御系统,在正常情况下,它能够保证人体不受外界病原微生物的侵害。通常说的人体免疫力就是指人体的免疫系统抵御外来病原微生物等侵害的能力。在人体免疫力正常的情况下,人体自身能够抵御相当多的病菌的侵害,避免对人体造成损伤。免疫力在人体生命机制中发挥重要的作用,而人体的营养、劳累、心情、环境、疾病、用药、辐射等导致自身的免疫力下降。越来越多研究表明,中药对人体免疫力的调节越来越发挥重要作用。本实验结果显示,本发明泡茶可提高环磷酰胺致免疫力下降小鼠免疫器官的脏器指数、巨噬细胞吞噬能力及T细胞的增值能力,可初步证实本发明泡茶对免疫力低下小鼠的免疫力有增强作用。
菊花的主要成分有挥发油(0.20-/0-0.85%)、腺嘌呤、胆碱、水苏碱、菊苷及黄酮类化合物。挥发油主要有龙脑、樟脑、菊酮和醋酸龙脑酷等成分,黄酮类成分有木樨草素、芹菜素、刺槐素等。此外,菊花中还含有丰富的维生素、氨基酸、微量元素等。杭白菊中维生素E含量较高。
《本草纲目》:风热,目疼欲脱,泪出,养目去盲,作枕明目。《本经》:诸风头眩肿痛,目欲脱,泪出,皮肤死肌,恶风湿痹。久服利血气,轻身耐老延年。《别录》:疗腰痛去来陶陶,除胸中烦热,安肠胃,利五脉,调四肢。《本草衍义》:近世有二十余种,惟单叶花小而黄,绿叶色深小而薄,应候而开者是也。
菊花疏风较弱,清热力佳,用于外感风热常配桑叶同用,也可配黄芩、山栀治热盛烦燥等症。菊花治目赤肿痛,无论属于肝火或风热引起者,均可应用,因本品既能清肝火,又能散风热,常配合蝉衣、白蒺藜等同用。如肝阴不足,眼目昏花,则多配生地、杞子等同用。菊花清热解毒之功甚佳,为外科要药,主要用于热毒疮疡、红肿热痛之症,特别对于疔疮肿痛毒尤有良好疗效,既可内服,又可捣烂外敷。临床上常与地丁草、蒲公英等清热解毒之品配合应用。菊花能平降肝阳,对肝阳上亢引起的头目眩晕,往往与珍珠母、葛藤等配伍应用。
菊花一药,主要分白菊、黄菊、野菊。黄、白两菊,都有疏散风热、提高免疫力、清热解毒的功效。白菊花味甘、清热力稍弱,长于提高免疫力;黄菊花味苦,泄热力较强,常用于疏散风热;野菊花味甚苦,清热解毒的力量很强。野菊的茎、叶,功用与花相似,无论内服与外敷,都有功效。桑叶与菊花,均能疏散风热,清泄肺肝,故在外感风热、发热头痛及目赤肿痛等症,两药往往相辅为用。但桑叶疏风清肺的功效较好,故治肺燥咳嗽,往往用桑叶而不用菊花;菊花则长于平肝阳,且能清热解毒。本发明使用白菊。
桑叶是桑科植物桑的干燥叶。初霜后采收,除去杂质,晒干而得,是一种发散风热药,既可内服,也可外敷。其性寒,味甘、苦,有疏散风热、清肺润燥、清肝明目的功效,可治疗风热感冒,肺热燥咳,头晕头痛,目赤昏花的病症。现代中、西医把桑叶和桑叶生物制剂作为改善糖尿病及其他各种疑难杂症的药物而使用,认为其药效极为广泛。有清肺润燥、止咳、去热、化痰、治盗汗;补肝、清肝明目、治疗头晕眼花、失眠、消除眼部疲劳;消肿、清血‘治疗痢疾、腹痛、减肥、除脚气、利大、小肠;抗应激、凉血、降血压、降血脂、预防心肌梗塞、脑溢血、祛头痛、长发;降血糖、抗糖病等。
桑寄生(学名:Taxillus sutchuenensis(Lecomte)Danser),别称桃树寄生,苦楝寄生等。嫩枝、叶密被褐色或红褐色星状毛,有时具散生叠生星状毛,小枝黑色,无毛,具散生皮孔。产于云南、四川、甘肃、陕西、山西、河南、贵州、湖北、湖南等地。有祛风湿,益肝肾,强筋骨,安胎的功效。
杜仲游离氨基酸极少,含有的少量蛋白质,是和绝大多数食品类似的完全蛋白,即能够水解检出对人体必需的8种氨基酸。测定了杜仲所含的15种矿物元素,其中有锌、铜、铁等微量元素,及钙、磷、钾、镁等宏量元素。药用杜仲,即为杜仲科植物杜仲的干燥树皮,是中国名贵滋补药材。其味甘,性温。有补益肝肾、强筋壮骨、调理冲任、固经安胎的功效。可治疗肾阳虚引起的腰腿痛或酸软无力,肝气虚引起的胞胎不固,阴囊湿痒等症。在《神农本草经》中被列为上品。
五味子为木兰科植物五味子Schisandra chinensis(Turcz.)Baill.或华中五味子Schisandra sphenanthera Rehd.et Wils.的干燥成熟果实。前者习称“北五味子”,后者习称“南五味子”。秋季果实成熟时采摘,晒干或蒸后晒干,除去果梗及杂质。唐等《新修本草》载“五味皮肉甘酸,核中辛苦,都有成味”,故有五味子之名。五味子分为南、北二种。古医书称它荎蕏、玄及、会及,最早列于神农本草经上品中药,能滋补强壮之力,药用价值极高,有强身健体之效,与琼珍灵芝合用治疗失眠。
地骨皮清热,凉血。治虚劳潮热盗汗,肺热咳喘,吐血,衄血,血淋,消渴,高血压,痈肿,恶疮。《本经》:″主五内邪气,热中消渴,周痹。″《别录》:″主风湿,下胸胁气,客热头痛,补内伤大劳嘘吸,坚筋,强阴,利大小肠,耐寒暑。″
栀子(学名:Gardenia jasminoides Ellis)别名:黄栀子、山栀、白蟾,是茜草科植物栀子的果实。栀子的果实是传统中药,属卫生部颁布的第1批药食两用资源,具有护肝、利胆、降压、镇静、止血、消肿等作用。在中医临床常用于治疗黄疸型肝炎、扭挫伤、高血压、糖尿病等症。含番红花色素苷基,可作黄色染料。
益母草味辛苦、凉,活血、祛淤、调经、消水,治疗妇女月经不调,胎漏难产,胞衣不下,产后血晕,瘀血腹痛,崩中漏下,尿血、泻血,痈肿疮疡。益母草有利尿消肿、收缩子宫作用的作用,是历代医家用来治疗妇科病的要药。益母草可全草入药,有效成分为益母草素,益母草含益母草碱、水苏碱、益母草定、益母草宁等多种生物碱及苯甲酸、氯化钾等。益母草制剂有兴奋动物子宫的作用,与脑垂体后叶素相似,益母草浸膏及煎剂对子宫有强而持久的兴奋作用,不但能增强其收缩力,同时能提高其紧张度和收缩率。
夏枯草辛、苦,寒。归肝、胆经,功效;清热泻火,明目,散结消肿。目赤肿痛、头痛眩晕、目珠夜痛。本品苦寒主入肝经,善泻肝火以明目。用治肝火上炎,目赤肿痛,可配桑叶、菊花、决明子等药用。本品清肝明目之中,略兼养肝,配当归、枸杞子,可用于肝阴不足,目珠疼痛,至夜尤甚者;亦可配香附、甘草用,如夏枯草散(《张氏医通》)。
马齿苋,拉丁学名:Portulaca oleracea L.为马齿苋科一年生草本植物。肥厚多汁,无毛,高10~30cm,生于田野路边及庭园废墟等向阳处。国内各地均有分布。该种为药食两用植物。全草供药用,有清热利湿、解毒消肿、消炎、止渴、利尿作用;种子明目。现代研究,马齿苋还含有丰富的SL3脂肪酸及维生素A样物质。SL3脂肪酸是形成细胞膜,尤其是脑细胞膜与眼细胞膜所必需的物质;维生素A样物质能维持上皮组织如皮肤、角膜及结合膜的正常机能,参与视紫质的合成,增强视网膜感光性能,也参与体内许多氧化过程。
白芍养血柔肝,缓中止痛,敛阴收汗。治胸腹胁肋疼痛,泻痢腹痛,自汗盗汗,阴虚发热,月经不调,崩漏,带下。《日华子本草》:″治风补痨,主女人一切病,并产前后诸疾,通月水,退热除烦,益气,治天行热疾,瘟瘴惊狂,妇人血运,及肠风泻血,痔瘘发背,疮疥,头痛,明目,目赤,胬肉。″白芍提取物对D-半乳糖胺所致肝损伤和SGPT升高有明显的对抗作用,能使SGPT降低,并使肝细胞的病变和坏死恢复正常.白芍的乙醇提取物能使黄曲霉素B1引起的大鼠急性肝损伤所表现出来的乳酸脱氢酶及同功酶的总活性升高得以降低.白芍总甙可抑制四氯化碳所致小鼠血浆GPT和乳酸脱氢酶升高,并对肝脏组织噬酸性变性、坏死有一定的对抗作用.有人认为,四氯化碳所致的肝损伤是因细胞膜结构发生过氧化作用而破坏,使血中谷丙转氨酶和乳酸脱氢酶升高,白芍总甙可能对肝细胞损伤具有保护作用,因此可使转氨酶降低.
玉竹,学名:Polygonatum odoratum(Mill.)Druce,为百合科多年生草本植物。根茎横走,肉质黄白色,密生多数须根。叶面绿色,下面灰色。花腋生,通常1~3朵簇生。原产中国西南地区,但野生分布很广。耐寒,亦耐阴,喜潮湿环境,适宜生长于含腐殖质丰富的疏松土壤。《本草经集注》云“茎干强直,似竹箭杆,有节。”故有玉竹之名。植物的根茎可供药用,中药名亦为玉竹,秋季采挖,洗净,晒至柔软后,反复揉搓,晾晒至无硬心,晒干,或蒸透后,揉至半透明,晒干,切厚片或段用。玉竹提取类黄酮物质与桑叶提取物脱氧野尻霉素结合形成一种新物质——洗胰清糖素(cics),具有降血糖、血脂、血压等作用
山茱萸果肉内含有16种氨基酸,另外,含有大量人体所必需的元素。另外,含有生理活性较强的皂甙原糖、多糖、苹果酸、酒石酸、酚类、树脂、鞣质和维生素A、C等成分。其味酸涩,具有滋补、健胃、利尿、补肝肾,益气血等功效。主治血压高、腰膝酸痛、眩晕耳鸣、阳萎遗精、月经过多等症。山茱萸的成熟干燥果实,去核后即为名贵药材山芋肉。果药入药,为收敛性补血剂及强壮剂;可健胃、补肝肾、治贫血、腰痛、神经及心脏衰弱等症。其性味酸涩、入肝、肾经。酸涩收敛,有滋肝补肾、固肾涩精的作用,适用于肝肾不足所致的腰膝酸软、遗精滑泄、眩晕耳鸣之症。茱萸肉含有丰富的营养物质和功能成分,明代李时珍的《本草纲目》集历代医家应用山茱萸的经验,把山茱萸列为补血固精、补益肝肾、调气、补虚、明目和强身之药
莪术辛、苦,温。归肝、脾经。功效主治破血行气,消积止痛。用于血瘀腹痛、肝脾肿大、心腹胀痛,积聚,妇女血瘀经闭,跌打损伤作痛饮食积滞。行气止痛,破血消积:用于气滞血瘀之经闭、胸胁痛、腹痛及症瘕肿块等。常配三棱。消食化积:用于饮食积滞之胃腹胀痛,常配焦麦芽、焦槟榔。根茎称“莪术”,供药用,主治“气血凝滞,心腹胀痛,症瘕,积聚,宿食不消,妇女血瘀经闭,跌打损伤作痛。”块根称“绿丝郁金”,有行气解郁,破瘀,止痛的功用。
红景天:拉丁文学名Rhodiola rosea,英文名Roseroot,是景天科多年生草木或灌木植物,生长在海拔800——2500米高寒无污染地带的珍稀野生植物。由于其生长环境恶劣,如缺氧、低温干燥、狂风、受紫外线照射、昼夜温差大,因而具有很强的生命力和特殊的适应性。为亚洲地区常用传统药材,具有刺激神经系统、增加工作效率、消除疲劳和预防高山症等作用。已确认的红景天超过二百个品种,当中大约二十多种为亚洲传统医学的常用药,例如小花红景天、大花红景天、蔷薇红景天、圣地红景天等。尤其是蔷薇红景天,已被广泛研究。二十世纪六十年代苏联科学家发现,它具有适应原样作用,可以协助身体回复稳态。也就是说红景天能提高身体对抗各种来自化学、生物或物理因素的刺激。有关红景天的研究,除了传统的抗压功能外,科学家还专注一些新发现,包括抗癌及抗糖尿病等。明代李时珍《本草纲目》记载“红景天,本经上品,祛邪恶气,补诸不足”是“已知补益药中所罕见”。《中药大辞典》记载:红景天“性寒,味甘涩。活血止血,清肺止咳。治咳血,咯血,肺炎咳嗽。”《现代实用本草》言其作用有七个,一、中枢抑制作用。二、抗疲劳作用。三、强心作用。四、抗炎作用。五、抑制血糖升高作用。六、抗过氧化作用。七、抗微波辐射作用”。
丹皮,又名牡丹皮,中药名。为毛茛科植物牡丹干燥根皮。产于安徽、山东等地。秋季采挖根部,除去细根,剥取根皮,晒干。生用或炒用。《本草纲目》:“滋阴降火,解斑毒,利咽喉,通小便血滞。后人乃专以黄蘖治相火,不知丹皮之功更胜也。赤花者利,白花者补,人亦罕悟,宜分别之。”现代研究,所含牡丹酚及其以外的糖苷类成分均有抗炎作用;牡丹皮的甲醇提取物有抑制血小板作用;牡丹酚有镇静、降温、解热、镇痛、解痉等中枢抑制作用及抗动脉粥样硬化、利尿、抗溃疡等作用。
黄精是常用滋补中药,在我国已有2000多年的用药历史,为百合科黄精属多年生草本植物,药用其根茎。黄精性平、味甘,归脾、肺、肾经,具有补脾润肺、益气养阴之功效,用于治疗体虚乏力、心悸气短、肺燥干咳、体癣等症。近年来,人们对黄精及其黄精属植物的研究不断深入,已从黄精植物中分离得到的化学成分有生物碱、黄酮、醌类、木脂素、多糖、甾体皂苷及微量元素等。
具体实施例1:
菊花的制备:在9~11月采收品相好的白菊花,簸去杂质,洗净,晒干;将晒干的白菊花放入乙醇中萃取,作为组分1。
其他原料的制备:其他原料泡入10倍量乙醇中2-3天后,加热提取2次,成组分2。
混合:将制备好的白菊花萃取液和其他原料提取液混合,浓缩后,加糊精,作为口服液。
具体实施例2:
秋季将采集的白菊大约4000g切碎,将其浸泡置于有盖不锈钢桶内,加70%乙醇液,质量为粗颗粒的0.8-1倍,搅拌均匀,湿润密闭放置1小时以上,使充分膨胀;将渗漉筒底部滤板用纱布袋包裹铺平后再将湿润膨胀后的药物样品拌松弄散,然后用不锈钢勺盛粉,均匀的装入渗漉筒,装10-12厘米厚,用T型棒压匀,再按上述操作,一层一层的装入,适当加压,药粉填装不得超过渗漉筒的2/3高处;药粉面上盖不锈钢孔板压牢,打开渗漉筒下面的放料阀,并放一容器,然后缓缓加入70%乙醇液;待排出药粉粉粒之间的空气,并有乙醇流出约20L左右,关闭放料阀,盖上漉筒、浸渍24小时,然后开放料阀进行渗漉,控制渗漉速度一般为1000g药材每分钟流出2~3ml,滤液放入贮液缸内,并将排空时的乙醇液倒入贮液缸;将渗滤液合并静置,静置备用,作为组分1。将其余原料桑寄生1000g,黄精1000g,桑叶1000g,山茱萸1000g,莪术1000g,五味子1000g,杜仲1000g,玉竹1000g,马齿苋1000g,天花粉1000g,栀子1000g,地骨皮1000g,益母草1000g,合欢皮1000g,红景天1000g,丹皮1000g,泡入10倍量乙醇中2-3天后,加热提取2次,每次1-2小时,取上清液,合并提取液,100-110目滤过,再经截流分子量为6000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.25的滤液,静置备用,成组分2。将上述步骤提取的两种提取液,放入双效真空浓缩器中混合,先将滤液浓缩至80℃时相对密度为1.32的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含0.1g浸膏,加糊精调和消毒杀菌后制备成口服液。
具体实施例3:
秋季将采集的白菊大约5000g切碎,将采集的白菊花泡入10倍量乙醇中2-7天后,加热提取2次,每次1-2小时,取上清液,合并提取液,100-110目滤过,再经截流分子量为6000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩至膏状,静置备用,成组分1。将其余原料药材桑寄生1100g,黄精1200g,桑叶1100g,山茱萸1100g,莪术1200g,五味子1200g,杜仲1100g,玉竹1200g,马齿苋1100g,天花粉1200g,栀子1200g,地骨皮1100g,益母草1100g,合欢皮1100g,红景天1100g,丹皮1100g,混合,切碎过100~120目筛,过筛后细粉备用,粗颗粒放入耐酸碱浸渍锅,在室温下,与70度以上乙醇一起浸渍15~30天,然后加热回流提取2次,每次1~2小时,将2次提取液合并静置,过滤,分离后取滤液;用纱布过滤,残渣中加入50-60%乙醇,60℃-70℃继续浸提2h,每10min搅拌一次,纱布过滤,合并浸提液,浓缩成糊状成为组分2。将上述步骤提取的两种提取液,放入双效真空浓缩器中混合,先将滤液浓缩至80℃时相对密度为1.32的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含0.1g浸膏,加糊精调和消毒杀菌后制备成口服液。
药理学毒性试验
急性毒性实验
一、试验材料:
动物:昆明种小鼠,体重21-24g,雌雄各半,山东大学生物试验室育种。实验物:本发明煎煮液。
二、方法:
1、LD50计算:采用改良寇氏法,将小鼠随机分成5组,每组10只,雌雄各半,将本发明加蒸馏水溶解,配成最大浓度,按小鼠最大允许容量给药,所给剂量按生药量依次为18,14.4,11.5,9.2,7.4(g.kg-1),在动物禁食(不禁水)18小时后,一日内分两次给药(间隔半小时),每次0.5ml,观察动物死亡情况。
2、最大耐受剂量测定(MTD值):取小鼠20只,雌雄各10只。将本发明加蒸馏水溶解,配成最高浓度,按动物的最大耐受量,以注射灌喂器能抽动为准。在动物禁食(不禁水)18小时后,一日内分两次给药(间隔半小时),每次0.5ml(每ml含生药0.36g),总药量为18g生药/kg.d,相当临床成人50Kg体重用量的300倍。给药后连续观察7天。
三、试验结果:
在LD50计算中当用最大允许浓度和最大允许容量给予小鼠时(18g/Kg.d),未见小鼠死亡,即未测出LD50,只可求最大耐受剂量,在7天观察期中,动物其食欲、活动、毛色、精神状态等皆正常,发育正常,未见有死亡。即选用相当于临床剂量的300倍药量,并无不良反应发生,表明急性毒性极小,MTD>18g/Kg.d。
实验例2:长期毒性实验资料
本发明的煎煮剂经灌胃给药6个月的动物长期毒性试验结果:SD大鼠分成三组,每组30只,雌雄各半(分成高、中、低三个剂量组,每组10只),其中第一组经灌胃给生理盐水;第二组经灌胃给本发明的剂量为0.25g、2.5g和12.5g/kg.d;第三组经灌胃给洛伐他汀的剂量为0.5mg、5.0mg和50.0mg/kg.d。在给药期间,分别观察各组动物给药后的临床表现、血液学、血生化、脏器系数和组织病理学等指标进行药物毒性的评价。研究结果:主要毒性反应表现在洛伐他汀50mg/kg.d和5.0mg组,表现在给药后SD大鼠出现了流涎、毛蓬松、忙碌、腹泻、踏脚等反应和症状,总摄食量和体重减轻;血液检查显示白细胞总数有所增加,红细胞总数、血红蛋白含量和血小板计数明显下降(P均<0.05);血液生化检查显示ALT、AST、ALP和CK升高1~8倍(P均<0.05),肌酐和尿素氮有所升高(P均<0.05),但未引起动物死亡;组织病理学分析结果显示洛伐他汀50mg/kg.d组出现了与人相似的肝肾病理改变。而生理盐水组和本发明0.25g、2.5g和12.5g/kg.d三个剂量组和洛伐他汀0.5mg/kg.d剂量组在整个给药期间均未出现类似反应,在恢复期观察期间,出现反应的各组动物的症状逐渐消失恢复正常状态。可见本发明不但能够降低洛伐他汀的毒副作用,而且可使洛伐他汀的临床无毒剂量增加至5~25倍(P均<0.01)。
试验例3:累积毒性实验:
本发明煎煮剂对小鼠按7.69、19.18和43.21g生药/kg连续用药15周(1.0ml/100g体重,每天2次)及停药3周后,结果表明:本发明中药制剂对大鼠的毛发、行为、大小便、体重、脏器重量、血象、肝肾功能、血糖、血脂等指标均无明显影响,脏器肉眼没有发现异样变化和组织学检查结果表明,用药15周及停药3周后,大鼠各脏器均无明显改变。说明本发明中药制剂对大鼠长期用药后毒性小,停药后也没有异样反应,应用安全。
药理学实验说明:
临床实验:本发明配方中含黄精、熟地与绞股蓝药材,具有补气补血,调和气血之功效。我们观察本发明对免疫低下小鼠免疫功能的影响,现将研究结果报道如下。
1材料与方法
1.1实验材料本发明(自制,规格:8g/瓶,按具体实施例2的方法制备),注射用环磷酰胺(江苏恒瑞医药股份有限公司产,规格:0.1g,批号:20080602),植物血凝素(购自Sigma公司),RPMI-1640(购自美国Hyclone公司),新生小牛血清(中国云南邓川蝶泉生物血清厂出品,批号:20080607002),四噻唑盐(MTT,),二甲基亚砜(DMSO);昆明小鼠(山东大学实验动物厂产);酶标仪(美国Thermo Fisher Scientific Co.,Ltd产,型号:MultiskanMK3),CO2培养箱(美国Thermo Fisher Scientific Co.,Ltd产,型号:Thermo Scientific3110)。
1.2实验方法
1.2.1药液的配制:按实施例2的制备方法制备。
1.2.2分组:将72只小鼠分为6组,空白对照组(NS,0.9%氯化钠注射液20ml/kg),环磷酰胺(CTX)对照组(40mg/kg),CTX+本发明2.4g/kg高剂量组(高剂量组),CTX+本发明0.6g/kg低剂量组,每组12只。各组分别灌胃1次/d,1ml/d连续14d后检测本发明对小鼠免疫器官、巨噬细胞吞噬功能、淋巴细胞增殖情况的影响。
1.2.3免疫功能检测指标
1.2.3.1免疫器官质量:颈椎脱臼处死小鼠后称取体质量,立即取出胸腺与脾脏,用滤纸吸干残血后称重(mg),以胸腺、脾脏的质量(mg)与体质量(g)之比,作为胸腺、脾脏的指数,胸腺(脾)脏器指数=脏器质量(mg)/体质量(g)。
1.2.3.2吞噬功能:处死动物前3d,腹腔注射5%的淀粉肉汤激活小鼠巨噬细胞,采用半体内法检测腹腔巨噬细胞吞噬功能,以100个巨噬细胞中吞噬鸡红细胞的巨噬细胞数(吞噬率)及每个巨噬细胞吞噬鸡红细胞的个数(吞噬指数)作为评价指标。
1.2.3.3T淋巴细胞增殖能力的检测(MTT法)Con A刺激小鼠脾淋巴细胞增殖能力的检测:颈椎脱臼处死小鼠后无菌条件下取出脾脏,用0.9%氯化钠溶液冲洗脾表面血液,置于乳钵中,加入RPMI1640培养液,研磨成单细胞悬液,以1000r·min-1转速离心弃上清液,用Hanks′液洗涤2次,重悬于RPMI1640培养液中。调节细胞浓度至3×106个/ml,分两孔加入24孔培养板中,每孔1ml。一孔加入75μl ConA液,另一孔作为对照,置37℃、5%CO2培养箱内培养72h,终止培养前4h每孔加入10μlMTT,培养结束后,吸弃上清,每孔加入DMSO 1ml,酶标仪于570nm测OD值,以加ConA孔的OD值减去不加ConA孔的OD值表示淋巴细胞增殖能力。
1.3统计学方法应用SPSS13.0软件对数据进行分析,计量资料用(-x±s)表示,采用方差分析。检验水准为α=0.05。
2结果
2.1本发明对小鼠免疫器官质量的影响CTX对照组免疫器官胸腺、脾脏指数均低于空白对照组,与空白对照组比较差异有统计学意义(P<0.01)。本发明高、低剂量组免疫器官胸腺、脾脏指数明显高于CTX对照组,与CTX对照组比较,差异有统计学意义(P<0.05,见表1)。
表1本发明对电离辐射损伤小鼠免疫器官脏器指数的影响(x±s,mg/g)
组别 | 小鼠(只) | 胸腺指数 | 脾指数 |
空白对照组 | 12 | 8.32±0.37 | 7.35±0.43 |
CTX对照组 | 12 | 4.26±0.17△ | 4.35±0.23△ |
高剂量组 | 12 | 6.48±0.28** | 5.89±0.24** |
低剂量组 | 12 | 5.81±0.21** | 4.72±0.21* |
注:与空白对照组比较,△P<0.01;与CTX对照组比较,*P<0.05,**P<0.01。CTX=环磷酰胺
2.2本发明对小鼠单核-腹腔巨噬细胞吞噬能力的影响CTX对照组吞噬百分率、吞噬指数均低于空白对照组,与空白对照组比较差异有统计学(P<0.01),本发明高、低剂量组吞噬百分率、吞噬指数明显高于CTX对照组,与CTX对照组比较,差异有统计学(P<0.05,见表2)。
表2本发明对小鼠腹腔巨噬细胞吞噬功能与淋巴细胞增殖的影响(-x±s)
注:与空白对照组比较,△P<0.01;与CTX对照组比较,*P<0.05,**P<0.01
人体免疫是人体对外界的病原微生物等的防御机能,或者说是防御系统,在正常情况下,它能够保证人体不受外界病原微生物的侵害。通常说的人体免疫力就是指人体的免疫系统抵御外来病原微生物等侵害的能力。在人体免疫力正常的情况下,人体自身能够抵御相当多的病菌的侵害,避免对人体造成损伤。免疫力在人体生命机制中发挥重要的作用,而人体的营养、劳累、心情、环境、疾病、用药、辐射等导致自身的免疫力下降。越来越多研究表明,中药对人体免疫力的调节越来越发挥重要作用。本实验结果显示,本发明泡茶可提高环磷酰胺致免疫力下降小鼠免疫器官的脏器指数、巨噬细胞吞噬能力及T细胞的增值能力,可初步证实本发明对免疫力低下小鼠的免疫力有增强作用。
菊花不但可以有效的健脾润肺降脂、活血化瘀、健脾润肺、降血脂、降血压、降低胆固醇、降低血糖,使血液的成份得到净化,而且还可以改善微循环、降低毛细血管的脆性,降低其通透性,主治阴虚劳嗽;肺燥咳嗽;脾虚乏力;食少口干;再加上一些活血化瘀,健脾利湿养阴的中药材,这些药材大多口感清淡,不影响菊花的味道,没有难闻难以下咽的中药味,使人易于接受,可以长期服用,能较好的改善亚健康人群易感冒、眼睛酸涩、脾虚乏力;食少口干;消渴;肾亏腰膝酸软;阳痿遗精;耳鸣目暗;须发早白;体虚赢瘦;风癞癣疾的症状,尤其适合老人、儿童、身体羸弱的病患,更能较好的达到提高免疫力的功效。
Claims (10)
1.一种提高免疫力的菊花口服液的制备方法,其特征在于,包括以下步骤:
a.菊花的萃取,作为组分1;
b.其他原料的制备,作为组分2;
c.将上述两种提取液组分1和组分2合并,浓缩后加糊精调和,消毒杀菌后制备成口服液。
2.根据权利要求1所述提高免疫力的菊花口服液的制备方法,其特征在于:所述步骤a中,秋季将采集的白菊切碎,将其浸泡置于有盖不锈钢桶内,加70%乙醇液,质量为粗颗粒的0.8-1倍,搅拌均匀,湿润密闭放置1小时以上,使充分膨胀;将渗漉筒底部滤板用纱布袋包裹铺平后再将湿润膨胀后的药物样品拌松弄散,然后用不锈钢勺盛粉,均匀的装入渗漉筒,装10-12厘米厚,用T型棒压匀,再按上述操作,一层一层的装入,适当加压,药粉填装不得超过渗漉筒的2/3高处;药粉面上盖不锈钢孔板压牢,打开渗漉筒下面的放料阀,并放一容器,然后缓缓加入70%乙醇液;待排出药粉粉粒之间的空气,并有乙醇流出约20L左右,关闭放料阀,盖上漉筒、浸渍24小时,然后开放料阀进行渗漉,控制渗漉速度一般为1000g药材每分钟流出2~3ml,滤液放入贮液缸内,并将排空时的乙醇液倒入贮液缸;将渗滤液合并静置,静置备用,作为组分1。
3.根据权利要求1所述提高免疫力的菊花口服液的制备方法,其特征在于,所述步骤b中,将其余原料泡入重量10倍量乙醇中2-3天后,加热提取2次,每次1-2小时,取上清液,合并提取液,100-110目滤过,再经截流分子量为6000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.25的滤液,静置备用,成组分2。
4.根据权利要求1所述提高免疫力的菊花口服液的制备方法,其特征在于,所述步骤c中,将上述步骤提取的两种提取液,放入双效真空浓缩器中混合,先将滤液浓缩至80℃时相对密度为1.32的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含0.1g浸膏,加糊精调和,消毒杀菌后制备成口服液。
5.一种提高免疫力的菊花口服液的制备方法,其特征在于,包括以下步骤:
a.菊花的制备,作为组分1;
b.将所述其余原料药切碎提取作为组分2;
c.将组分1和组分2混合,浓缩后加适量蜂蜜调和,紫外线消毒杀菌后装瓶。
6.根据权利要求5所述提高免疫力的菊花口服液的制备方法,其特征在于,所述步骤a中,将采集的白菊花泡入10倍量乙醇中2-7天后,加热提取2 次,每次1-2小时,取上清液,合并提取液,100-110目滤过,再经截流分子量为6000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩至膏状,静置备用,成组分1。
7.根据权利要求5所述提高免疫力的菊花口服液的制备方法,其特征在于,所述步骤b中,将其余原料药材混合,切碎过100~120目筛,过筛后细粉备用,粗颗粒放入耐酸碱浸渍锅,在室温下,与70度以上乙醇一起浸渍15~30天,然后加热回流提取2次,每次1~2小时,将2次提取液合并静置,过滤,分离后取滤液;用纱布过滤,残渣中加入50-60%乙醇,60℃-70℃继续浸提2h,每10min搅拌一次,纱布过滤,合并浸提液,浓缩成糊状成为组分2。
8.一种提高免疫力的菊花口服液,其特征在于,包括以下重量份的原料药:菊花10~50份,桑寄生10~20份,黄精10~20份,桑叶10~20份,山茱萸10~20份,莪术10~20份,五味子10~20份,杜仲10~20份,玉竹10~20份,马齿苋10~20份,天花粉10~20份,栀子10~20份,地骨皮10~20份,益母草10~20份,合欢皮10~20份,红景天10~20份,丹皮10~20份。
9.根据权利要求8所述提高免疫力的菊花口服液,其特征在于,所述菊花口服液中还包括以下重量份的原料药:菊花10~40份,桑寄生10~15份,黄精10~15份,桑叶10~15份,山茱萸10~15份,莪术10~15份,五味子10~15份,杜仲10~15份,玉竹10~15份,马齿苋10~15份,天花粉10~20份,栀子10~20份,地骨皮10~20份,益母草10~20份,合欢皮10~20份,红景天10~20份,丹皮10~20份。
10.根据权利要求8所述提高免疫力的菊花口服液,其特征在于,所述菊花口服液中也包括以下重量份的原料药:菊花10~30份,桑寄生10~20份,黄精10~20份,桑叶10~20份,山茱萸10~20份,莪术10~20份,五味子10~20份,杜仲10~20份,玉竹10~20份,马齿苋10~20份,天花粉10~15份,栀子10~15份,地骨皮10~15份,益母草10~15份,合欢皮10~15份,红景天10~15份,丹皮10~15份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610620899.6A CN106418529A (zh) | 2016-08-02 | 2016-08-02 | 提高免疫力的菊花口服液制备方法及其口服液 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610620899.6A CN106418529A (zh) | 2016-08-02 | 2016-08-02 | 提高免疫力的菊花口服液制备方法及其口服液 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106418529A true CN106418529A (zh) | 2017-02-22 |
Family
ID=58184316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610620899.6A Withdrawn CN106418529A (zh) | 2016-08-02 | 2016-08-02 | 提高免疫力的菊花口服液制备方法及其口服液 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106418529A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108634259A (zh) * | 2018-06-26 | 2018-10-12 | 洛阳顺势药业有限公司 | 一种具有增加免疫力的保健口服液及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1086400A (zh) * | 1993-09-30 | 1994-05-11 | 刘金宝 | 固体天然植物珍花饮品 |
CN101703228A (zh) * | 2009-11-10 | 2010-05-12 | 赵祎乾 | 一种增强免疫力的保健组合物及其制备方法 |
CN105125736A (zh) * | 2015-09-07 | 2015-12-09 | 无限极(中国)有限公司 | 一种保肝明目功效的组合物及其制备方法 |
CN105708970A (zh) * | 2016-02-01 | 2016-06-29 | 中国医学科学院药用植物研究所 | 一种具有降血糖功能的保健食品 |
CN105727032A (zh) * | 2016-03-30 | 2016-07-06 | 黄山树德堂食品饮料有限公司 | 一种平肝明目的保健饮料及其制备方法 |
-
2016
- 2016-08-02 CN CN201610620899.6A patent/CN106418529A/zh not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1086400A (zh) * | 1993-09-30 | 1994-05-11 | 刘金宝 | 固体天然植物珍花饮品 |
CN101703228A (zh) * | 2009-11-10 | 2010-05-12 | 赵祎乾 | 一种增强免疫力的保健组合物及其制备方法 |
CN105125736A (zh) * | 2015-09-07 | 2015-12-09 | 无限极(中国)有限公司 | 一种保肝明目功效的组合物及其制备方法 |
CN105708970A (zh) * | 2016-02-01 | 2016-06-29 | 中国医学科学院药用植物研究所 | 一种具有降血糖功能的保健食品 |
CN105727032A (zh) * | 2016-03-30 | 2016-07-06 | 黄山树德堂食品饮料有限公司 | 一种平肝明目的保健饮料及其制备方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108634259A (zh) * | 2018-06-26 | 2018-10-12 | 洛阳顺势药业有限公司 | 一种具有增加免疫力的保健口服液及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102048933B (zh) | 一种治疗小儿腹泻的中药组合物及其制备方法 | |
CN102988638B (zh) | 一种青钱柳叶降脂降糖保健茶及其制备方法 | |
CN103719498B (zh) | 一种提高免疫力的黄精保健茶及其制备方法 | |
CN104435775A (zh) | 一种中药保健酒及其制备方法 | |
CN105727032A (zh) | 一种平肝明目的保健饮料及其制备方法 | |
CN104322617A (zh) | 一种辅助降血糖的饼干及其制备方法 | |
CN104305205B (zh) | 一种提高免疫力的菟丝子口服液及其制备方法 | |
CN105454576A (zh) | 茉莉花八宝茶及其制备方法 | |
CN103749821B (zh) | 一种提高免疫力的绞股蓝保健茶及其制备方法 | |
CN102886014A (zh) | 一种清血消炎的抗肿瘤药物 | |
CN104489172A (zh) | 一种提高免疫力的刺五加保健茶及其制备方法 | |
CN104383412A (zh) | 解郁养生中药酒及制备方法 | |
CN105831543A (zh) | 一种平肝明目的菊花保健饮料及其制备方法 | |
CN105341944A (zh) | 一种提高免疫力的丹参口服液及其制备方法 | |
CN105343593A (zh) | 一种降压降脂的夏枯草保健口服液及其制备方法 | |
CN105994840A (zh) | 一种铁皮石斛降压保健茶及其制作方法 | |
CN104397282A (zh) | 一种安神补脑的刺五加保健茶及其制备方法 | |
CN105056103A (zh) | 一种辅助降血脂降胆固醇的馒头及其制备方法 | |
CN106418529A (zh) | 提高免疫力的菊花口服液制备方法及其口服液 | |
CN106213514A (zh) | 一种提高免疫力的菊花保健口服液及其制备方法 | |
CN105343502A (zh) | 一种可提高免疫力的保健口服液 | |
CN109646665A (zh) | 杜仲清肺抗癌固体茶及其制备方法 | |
CN105166237A (zh) | 一种护肝养肝丹参叶保健茶及其制备方法 | |
CN106110030A (zh) | 降糖降脂的菊花口服液制备方法及其口服液 | |
CN106237128A (zh) | 延缓衰老的菟丝子口服液制备方法及其口服液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170222 |
|
WW01 | Invention patent application withdrawn after publication |